Drug Trial News

RSS

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma.

27 Jun 2011

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan.

27 Jun 2011

Positive results from Stealth's Bendavia Phase I renal impairment study

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia.

27 Jun 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced Phase III study results for linagliptin, demonstrating improved glycaemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately maintained.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Promising results of the Phase I clinical trial of the generic drug BCG to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego.

27 Jun 2011

Diabetic patients can benefit from basal insulin analogs

Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes.

27 Jun 2011

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced new data from a Phase 1b study of ZGN-433, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed a significant improvement in cardiovascular risk markers in severely obese subjects.

27 Jun 2011

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.

24 Jun 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

Lithium profoundly prevents the aggregation of toxic proteins and cell loss associated with Parkinson's disease (PD) in a mouse model of the condition.

24 Jun 2011

Nature News examines controversy surrounding Indian HPV vaccine trial

After four teenage girls involved in a clinical trial in India testing vaccines for human papillomavirus (HPV) died last year, the study "threatens to have a dual legacy: inflaming unfounded fears about a lifesaving vaccine and raising new questions about the management of medical research in the country," Nature News reports.

24 Jun 2011

Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma

Millennium: The Takeda Oncology Company today announced the presentation of results from an ongoing Phase II study of MLN8237, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory aggressive B-cell and T-cell non-Hodgkin lymphoma.

24 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

Oxytocin hormone holds promise for children with Prader-Willi syndrome

Prader-Willi syndrome is a rare genetic disorder which affects one child in 25,000. Children born with this syndrome have a range of complex neurological and developmental problems which continue into adult life. These can manifest as cognitive and behavioral difficulties, weight gain, problems in controlling their temper and attendant difficulties in socialization.

24 Jun 2011

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

24 Jun 2011

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine.

24 Jun 2011

Drug Trial News

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Positive results from Stealth's Bendavia Phase I renal impairment study

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Diabetic patients can benefit from basal insulin analogs

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

Nature News examines controversy surrounding Indian HPV vaccine trial

Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Oxytocin hormone holds promise for children with Prader-Willi syndrome

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News